Filing summary
Entity discrepancy: The supplied filing is Sigma Labs, Inc.’s Form 10-Q for the quarter ended June 30, 2014, not a filing for Nexttrip, Inc. The summary below reflects the filing text provided.
Business context and reporting period
Sigma Labs develops manufacturing and materials technologies, with a stated focus on in-process quality assurance and metal additive manufacturing (3D printing). During the periods reported, revenue came primarily from engineering consulting; the company reported no technology sales or licensing revenue. This unaudited quarterly report covers the three and six months ended June 30, 2014, with comparisons to 2013.
Financial performance and position
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Revenue | $114,813 | $307,985 | $229,642 | $472,249 |
| Gross profit | $30,074 | $158,436 | $89,014 | $235,770 |
| Gross margin | 26.2% | 51.4% | 38.8% | 49.9% |
| Net loss | $(1,795,909) | $(122,478) | $(2,262,815) | $(319,094) |
| Operating cash flow | Not stated for quarter | Not stated for quarter | $(463,463) | $13,662 |
- At June 30, cash was $4,321,415, versus $992,448 at December 31, 2013. Working capital was $4,349,548, versus $1,180,973.
- Total liabilities were $86,606, all current; the balance sheet reports no debt. Total assets were $4,514,712.
- Financing provided $3,793,302 net cash in the first half, mainly from stock sales. Cash increased by $3,328,967 over the period.
- Common shares issued were 612,241,061 at June 30, of which 610,966,061 were outstanding; the cover reports 618,241,061 issued and outstanding as of August 12.
Material changes versus prior comparable periods
- Revenue fell 63% in Q2 and 51% in the first half. Management attributed the decrease to a customer contract that was not renewed.
- Gross margin declined in both comparison periods as revenue fell faster than cost of services.
- First-half net loss increased to $2.26 million from $319,094. Q2 included $1,283,333 of warrant expense related to extending an investor warrant’s term; this was a major driver of the increased quarterly loss.
- First-half general and administrative expense increased to $416,179 from $282,349; payroll expense rose to $302,699 from $155,826, including a $175,000 first-quarter CEO performance bonus. Noncash stock compensation was $351,400, versus $116,700.
Outlook, risks, and unusual items
- Management expected to begin commercializing its IPQA technology in the remainder of 2014, but acknowledged it had not yet generated revenue from technology sales or licensing.
- Management estimated two active consulting contracts could generate up to approximately $87,000 in revenue during the remainder of 2014. It expected available funds and anticipated proceeds to cover administrative and operating expenses through 2015, but this depends on consulting revenue and/or further securities offerings.
- The company disclosed substantial going-concern uncertainty: it has sustained losses since inception, and continued operations depend on expanding income opportunities and access to capital. Management cautioned that further financing may be needed and is not assured; failure to obtain it could require curtailing or ceasing operations.
- After quarter-end, the company finalized a $724,000 purchase of an EOS Model 290 metal 3D printer, payable in three installments, with delivery expected in Q4 2014. Management said the equipment could support product development and prototyping or small-lot production services.
- Management expected general and administrative, payroll, and noncash compensation costs to increase as it expands and pursues commercialization. Fixed-price consulting contracts also carry risk if estimated performance costs are too low.
- Disclosure controls were assessed as effective at a reasonable assurance level; management reported no material change in internal control over financial reporting during the quarter. Legal proceedings and risk factors were listed as not applicable in this filing.
Important facts for investors to verify
- Confirm the issuer identity: the supplied document names Sigma Labs, Inc., not Nexttrip, Inc.
- Reconcile the June 30 share counts with the cover-page August 12 count, and assess dilution from shares and outstanding warrants.
- Review the warrant extension and its $1,283,333 expense, including the underlying valuation assumptions and accounting treatment.
- Assess whether consulting contracts, technology commercialization, and available financing can support the stated operating runway through 2015.
- Verify the printer purchase payment schedule, delivery, and expected contribution to commercialization or revenue.